OKYO Pharma Net Worth
OKYO Pharma Net Worth Breakdown | OKYO |
OKYO Pharma Net Worth Analysis
OKYO Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including OKYO Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of OKYO Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform OKYO Pharma's net worth analysis. One common approach is to calculate OKYO Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares OKYO Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing OKYO Pharma's net worth. This approach calculates the present value of OKYO Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of OKYO Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate OKYO Pharma's net worth. This involves comparing OKYO Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into OKYO Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if OKYO Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OKYO Pharma's net worth research are outlined below:
| OKYO Pharma had very high historical volatility over the last 90 days | |
| OKYO Pharma has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (16.8 M) with loss before overhead, payroll, taxes, and interest of (3.6 M). | |
| OKYO Pharma Ltd currently holds about 2.06 M in cash with (9.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| OKYO Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from accesswire.com: MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV |
OKYO Pharma Quarterly Good Will |
|
OKYO Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in OKYO Pharma Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to OKYO Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of August 2023 Upcoming Quarterly Report | View | |
| 31st of March 2023 Next Fiscal Quarter End | View |
Know OKYO Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OKYO Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OKYO Pharma Ltd backward and forwards among themselves. OKYO Pharma's institutional investor refers to the entity that pools money to purchase OKYO Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Barclays Plc | 2024-06-30 | 961 K | Hpm Partners Llc | 2024-06-30 | 12.8 K | Geode Capital Management, Llc | 2024-06-30 | 12.1 K | Hsbc Holdings Plc | 2024-06-30 | 11.9 K | Susquehanna International Group, Llp | 2024-06-30 | 11.1 K | Ubs Group Ag | 2024-06-30 | 1.9 K | Continuum Advisory, Llc | 2024-06-30 | 50.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Follow OKYO Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.54 M.Market Cap |
|
Project OKYO Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) |
When accessing OKYO Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures OKYO Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of OKYO Pharma's profitability and make more informed investment decisions.
Evaluate OKYO Pharma's management efficiency
OKYO Pharma has return on total asset (ROA) of (2.9187) % which means that it has lost $2.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.6851) %, meaning that it created substantial loss on money invested by shareholders. OKYO Pharma's management efficiency ratios could be used to measure how well OKYO Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Equity is likely to grow to 0, while Return On Tangible Assets are likely to drop (0.01). As of the 24th of November 2024, Intangible Assets is likely to grow to about 8.9 M, while Total Assets are likely to drop about 1.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.20) | (0.19) | |
| Net Current Asset Value | 42.89 | 38.12 | |
| Tangible Book Value Per Share | (0.20) | (0.19) | |
| Enterprise Value Over EBITDA | -2.7 K | -2.6 K | |
| Price Book Value Ratio | (7.34) | (7.70) | |
| Enterprise Value Multiple | -2.7 K | -2.6 K | |
| Price Fair Value | (7.34) | (7.70) | |
| Enterprise Value | 42.3 M | 40.2 M |
The strategic vision of OKYO Pharma Ltd management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Return On Equity (29.69) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OKYO Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on OKYO Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OKYO Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denoyer Bernard over six months ago Disposition of 1000000 shares by Denoyer Bernard of OKYO Pharma at 0.1045 subject to Rule 16b-3 | ||
Cerrone Gabriele M over a year ago Acquisition or disposition of OKYO Pharma securities by Cerrone Gabriele M | ||
Brancaccio John P over a year ago Purchase by Brancaccio John P of 16670 shares of OKYO Pharma |
OKYO Pharma Earnings per Share Projection vs Actual
OKYO Pharma Corporate Management
| Michael Beck | Founder | Profile | |
| Keeren Shah | Chief Officer | Profile | |
| PharmD Clementi | Chief Officer | Profile | |
| Rajkumar Patil | Chief Officer | Profile | |
| Gary Jacob | CEO Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.